Pfizer Inc.

Pfizer's revenue is driven by individual drug lifecycles, with forward visibility limited to patent-protection windows and subject to abrupt demand shifts. The COVID-19 product cycle created the clearest illustration of this dependence: revenues peaked at $101.2 billion in FY2022 and fell to $59.6 billion in FY2023 as government procurement normalized, a swing with no contractual floor.

No single product exceeded 12% of FY2024 revenue, with the four largest franchises (Eliquis at $7.3 billion, Prevnar family at $6.4 billion, Vyndaqel at $5.5 billion, and the Seagen oncology portfolio at $3.4 billion) each contributing below that level across genuinely distinct therapeutic categories. All revenues remain subject to pharmaceutical pricing and patent-expiry dynamics, limiting the diversification benefit.

The United States generated $37.1 billion in FY2025 revenue, approximately 59% of the $62.6 billion total, with developed international markets contributing $16.2 billion and emerging markets (including China at roughly 5% of global revenue) accounting for the remainder. Single-country concentration at this level leaves the business meaningfully exposed to US regulatory and reimbursement policy shifts.

Pharmaceutical manufacturing offers some incremental leverage on established drugs, but Pfizer's R&D base of approximately $10.7 billion in FY2023 (increasing in subsequent years for oncology and obesity) and substantial manufacturing infrastructure create a large fixed-cost structure that constrains operating leverage as high-revenue products cycle off. Scale economics are average for large-cap pharma, with no software-like or network-driven cost dynamics.

Key products serving chronic conditions, including Eliquis for atrial fibrillation and Vyndaqel for transthyretin amyloid cardiomyopathy, generate long-duration repeat-prescription demand without formal contractual obligation. Pfizer's vaccine franchises carry government schedule inclusion and public health mandate characteristics resembling mission-critical supply agreements, though most revenue remains prescription-driven rather than contractual.